Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 12.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 26,168 shares of the company’s stock after buying an additional 2,944 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Enliven Therapeutics were worth $668,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. FMR LLC increased its holdings in Enliven Therapeutics by 10.6% during the 3rd quarter. FMR LLC now owns 6,296,179 shares of the company’s stock valued at $160,804,000 after acquiring an additional 601,611 shares in the last quarter. First Turn Management LLC purchased a new position in shares of Enliven Therapeutics during the 2nd quarter worth approximately $9,657,000. Ally Bridge Group NY LLC acquired a new position in shares of Enliven Therapeutics during the 3rd quarter worth approximately $5,998,000. Marshall Wace LLP purchased a new stake in Enliven Therapeutics during the 2nd quarter worth about $4,489,000. Finally, Nicholas Investment Partners LP acquired a new position in shares of Enliven Therapeutics in the second quarter valued at approximately $1,310,000. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 2,000 shares of the business’s stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $25.33, for a total transaction of $50,660.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Joseph P. Lyssikatos sold 37,878 shares of Enliven Therapeutics stock in a transaction on Wednesday, October 9th. The shares were sold at an average price of $28.16, for a total value of $1,066,644.48. Following the sale, the insider now directly owns 1,016,035 shares in the company, valued at $28,611,545.60. The trade was a 3.59 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 129,195 shares of company stock valued at $3,581,772. Company insiders own 29.20% of the company’s stock.

Enliven Therapeutics Trading Down 1.7 %

Shares of ELVN opened at $22.47 on Friday. The firm has a market cap of $1.10 billion, a price-to-earnings ratio of -11.83 and a beta of 1.02. The stock has a 50 day moving average of $26.10 and a 200-day moving average of $24.19. Enliven Therapeutics, Inc. has a 52 week low of $10.90 and a 52 week high of $30.03.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $37.00 price objective on shares of Enliven Therapeutics in a report on Tuesday, October 1st. Robert W. Baird raised their target price on Enliven Therapeutics from $32.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday, November 15th. Finally, BTIG Research started coverage on Enliven Therapeutics in a research note on Friday, December 13th. They issued a “buy” rating and a $42.00 price target on the stock. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Enliven Therapeutics has a consensus rating of “Buy” and an average target price of $38.25.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.